摘要
目的观察地西他滨(DCA)联合阿霉素(ADR)对白血病K562细胞株多药耐药的逆转作用,探讨其治疗白血病的可行性。方法以不同浓度DCA+ADR处理K562/ADR细胞,用台盼蓝法观察药物对细胞生长曲线的影响,MTT法检测不同浓度DCA与ADR对K562/ADR细胞的杀伤活性,流式细胞技术检测细胞膜P糖蛋白及细胞内ADR浓度。结果 DCA+ADR对白血病K562细胞株多药耐药有明显逆转作用,可降低细胞膜P糖蛋白表达,提高K562耐药细胞株对ADR的敏感性。结论 DCA联合ADR可逆转白血病K562细胞株多药耐药性。
Objective To observe the reversal effect of decitabine and adriamycin（ADR） on the multidrug resistance of leukemia cell strain K562 and to explore its feasibility to treat leukemia.Methods K562/ADR cells were treated with different concentrations of decitabine and ADR.The impact of cell growth curve was observed by Trypan blue staining.Killer acticity of K562/ADR cell with different concentrations of decitabine or ADR was determined by MTT assay.The concentrations of P-glycoprotein in cell membrane and of ADR in cells were determined by FCM.Results Obvious reversal effects of DCA＋ADR on multidrug resistance in leukemia cell strain K562 were observed.Decitabine and ADR could decrease the expression of P-glycoprotein in cell membrane,and improve the sensibility of multidrug resistant cell strain K562 to ADR.Conclusions Decitabine and ADR could reverse the multidrug resistance on leukemia cell strain K562.
出处
《山东医药》
CAS
北大核心
2010年第17期19-21,共3页
Shandong Medical Journal
基金
天津市卫生局科技项目(05KY10)
